Rethinking Pharma Commercial Targeting with AI - with Philip Poulidis of ODAIA

Commercial life‑sciences teams are facing a widening gap between strong brand strategy and fragmented real‑world execution, driven by misaligned workflows, static targeting, and an inability to act at the speed patients move through their therapeutic journeys. In this episode, Philip Poulidis, CEO and Co-founder of ODAIA, unpacks how AI can close that gap by connecting brand intent to real‑time execution, enabling teams to prioritize the right HCPs, orchestrate engagement, and measure impact through outcomes rather than activity metrics. He highlights the practical shifts required to get there — from cross‑functional adoption and workflow‑embedded insights to attribution modeling, efficiency gains, and focused pilots that prove value quickly. This episode is sponsored by ODAIA. Learn how brands work with Emerj and other Emerj Media options at emerj.com/partner. Want to share your AI adoption story with executive peers? Click emerj.com/expert for more information and to be a potential future guest on the 'AI in Business' podcast!